Can pictures help surgeons talk about cancer risks?
NCT ID NCT06965192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether showing surgeons a visual decision-support tool before they meet with patients improves how they discuss risks and benefits of surgery. Up to 20 urologists and 200 patients with prostate or kidney cancer will take part. Researchers will compare conversations before and after the tool is introduced.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- visual decision-support tool
- What this could lead to
- If successful, this could improve how surgeons communicate risks and benefits of cancer surgery, leading to better-informed patients.
- What could go wrong
- This is a small, early-stage behavioral study with no direct treatment. Results may not change actual outcomes or apply to all settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Hanover Regional Medical Center
NOT_YET_RECRUITINGWilmington, North Carolina, 28401, United States
-
UNC Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?